Halozyme Therapeutics, Inc. HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. 10-K, Item 1
- Headquarters
- San Diego, CA
- CEO
- Helen Torley
- Next results
- around Jan 27, 2027
Where each dollar of revenue went, FY2025
Revenue of $1.4B through the costs to a net profit of $316.9M · income statement of the 10-K
HALO among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
8 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 17, 2026 against Feb 18, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +47.9% ($288.2M to $426.3M) vs revenue +37.6% ($1.0B to $1.4B), +10.4 pts apart
-
Critical audit matters changedNew this year: Valuation of the customer relationship intangible assets acquired in connection with the Elektrofi, Inc. acquisition (“As disclosed in Note 3 of the consolidated financial statements, the Company completed the acquisition of Elektrofi, Inc. (“Elektrofi”) on November 18, 2025, for total consideration of $810.4 million. The acquisition was accounted for as a business combination. The Company recorded intangible assets”). No longer listed: Table of Contents. Same as last year: Determination of Overall Transaction Price for Collaboration Agreements
-
Cash from operations $651.6M vs net income $316.9M (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Inventory +24.4% ($141.9M to $176.5M) vs revenue +37.6% ($1.0B to $1.4B), -13.2 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
8 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners’ costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
We may be required to initiate or defend against legal proceedings related to our intellectual property rights which may be time-consuming and result in substantial litigation expense. For example, in April 2025 we filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (“Merck”) in the U.S. District Court in New Jersey…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
Additionally, artificial intelligence (“AI”) based software is increasingly being used in the biopharmaceutical industry including by companies with which we compete. We are increasing the use of AI tools and technology and intend to integrate AI more broadly in our operations with the goal of increasing operational efficiencies,…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $660.1M | $829.3M | $1.0B | $1.4B |
| Net income | $202.1M | $281.6M | $444.1M | $316.9M |
| Operating cash flow | $240.1M | $388.6M | $479.1M | $651.6M |
| Free cash flow | $235.3M | $373.3M | $468.4M | $644.6M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.4B ▲ 37.6% in FY2025$316.9M ▼ 28.6% in FY2025$644.6M ▲ 37.6% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
SEC letterNov 14, 2026SEC asked 2 questions about Form 10-K for the Fiscal Year Ended December 31, 2014 letters Oct 26, 2015 to Jan 28, 2016
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Halozyme Therapeutics, Inc., San Diego, CA · from the 10-K filed Feb 17, 2026
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds.
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 5, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.